Anders Bach
Professor
Medicinal Chemistry
Jagtvej 162
2100 København Ø
Aktuel forskning
In the Bach Group, we develop biological active small-molecule inhibitors of protein-protein interactions involved in oxidative stress and which play key roles in inflammation and brain diseases (e.g. neurodegeneration and brain cancer). We evaluate the ‘druggability’ of selected targets, and aim at developing new high-quality chemical probes useful for pharmacological studies and for identifying new therapeutic principles against diseases.
Fragment-based drug discovery (FBDD) is a core theme of our research. We screen our library of fragments (i.e. small substructures of druglike molecules) using very sensitive biophysical methods, such as SPR and NMR. Promising and validated hits are optimized into lead molecules by medicinal chemistry, biostructural studies and pharmacology.
For more information about our research and open positions, please contact anders.bach@sund.ku.dk
ID: 1304261
Flest downloads
-
2754
downloads
PDZ domain-mediated interactions of G protein-coupled receptors with postsynaptic density protein 95: quantitative characterization of interactions
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Udgivet -
230
downloads
A high-affinity, bivalent PDZ domain inhibitor complexes PICK1 to alleviate neuropathic pain
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Udgivet -
148
downloads
Molecular architecture of the Jumonji C family histone demethylase KDM5B
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Udgivet